t(4:14) by FISH Genetic Translocation Test at Chughtai Lab

t(4:14) by FISH (Research purpose only) at Chughtai Lab

The t(4:14) by FISH (Research purpose only) at Chughtai Lab is a highly specialized molecular cytogenetic investigation designed to detect the t(4;14)(p16.3;q32) chromosomal translocation. This specific genetic aberration involves the fusion of the fibroblast growth factor receptor 3 (FGFR3) gene on chromosome 4 with the immunoglobulin heavy chain (IGH) locus on chromosome 14. In clinical oncology and hematopathology, this translocation is a critical prognostic marker, particularly in plasma cell dyscrasias such as Multiple Myeloma (MM). By utilizing Fluorescence In Situ Hybridization (FISH) technology, pathologists can identify this genetic rearrangement at the single-cell level with exceptional sensitivity and specificity. At Chughtai Lab, Pakistan’s leading diagnostic network, this test is performed using state-of-the-art molecular pathology infrastructure. The ‘Research purpose only’ designation indicates that while the test provides invaluable genetic insights, it is often utilized within specific clinical trials, investigational protocols, or as part of a comprehensive diagnostic workup requiring research-level validation. Understanding the presence of the t(4;14) translocation is paramount for hematologists and oncologists. It helps in classifying the disease subtype, predicting clinical outcomes, and designing risk-adapted therapeutic strategies. The test is typically performed on bone marrow aspirate samples or peripheral blood containing a high percentage of circulating plasma cells. Through this advanced molecular assay, Chughtai Lab continues to support clinicians and researchers across Pakistan in delivering precise, evidence-based healthcare.

Fluorescence In Situ Hybridization (FISH) has revolutionized the field of cytogenetics by bridging the gap between classical chromosome analysis (karyotyping) and molecular biology. While traditional karyotyping requires dividing cells in metaphase, FISH can be performed on interphase nuclei, which is particularly advantageous in multiple myeloma where plasma cells often have a low proliferative index in vitro. The t(4;14) translocation is present in approximately 15% of newly diagnosed multiple myeloma patients. It is considered a primary cytogenetic event, meaning it occurs early in the pathogenesis of the disease, often during the class switch recombination process in the germinal center. The resulting fusion gene leads to the dysregulation and overexpression of two key oncogenes: FGFR3 on the derivative chromosome 4 and MMSET (multiple myeloma SET domain-containing protein, also known as WHSC1) on the derivative chromosome 14. This dual oncogene activation drives clonal expansion, cell survival, and resistance to standard therapies, making its detection vital for patient management.

Clinical Procedure: What to Expect

Patient Preparation

• No fasting is generally required for this molecular test. Patients can eat and drink normally before sample collection.
• Inform your treating physician and the laboratory staff about all ongoing medications, especially blood thinners or anticoagulants, if a bone marrow biopsy is scheduled.
• Provide a complete clinical history, including previous hematological reports, bone marrow biopsy results, and suspected diagnosis of multiple myeloma or related plasma cell disorders.
• Ensure that all necessary consent forms for genetic and molecular testing are signed and submitted prior to sample collection.
• If the test is requested under a specific research protocol or clinical trial, bring the relevant documentation and referral letters from your oncologist.
• Wear comfortable clothing on the day of the procedure, especially if a bone marrow aspiration is to be performed at the collection center or hospital.

During the Procedure

The procedure begins with the collection of an appropriate biological specimen, which is typically a bone marrow aspirate or, in cases of high-burden plasma cell leukemia, a peripheral blood sample. A trained healthcare professional or hematologist performs the bone marrow aspiration under local anesthesia to minimize discomfort. Once the sample is collected in a specialized heparinized tube, it is immediately transported to the molecular genetics department at Chughtai Lab. In the laboratory, the cells are harvested and cultured if necessary, followed by slide preparation. Pathologists apply fluorescently labeled DNA probes specific to the FGFR3 and IGH loci. The slides undergo denaturation and hybridization, allowing the probes to bind to their complementary target sequences on chromosomes 4 and 14. After washing away unbound probes, the slides are analyzed under a high-resolution fluorescence microscope. The laboratory technologist and consultant pathologist count a specified number of interphase nuclei (usually 100 to 200 cells) to determine the percentage of cells harboring the t(4;14) translocation. The entire process is conducted under strict quality control measures to ensure clinical accuracy and reproducibility.

When is a t(4:14) by FISH Performed?

Diagnosis and Risk Stratification of Multiple Myeloma

Physicians request the t(4;14) FISH test during the initial diagnostic workup of patients suspected of having multiple myeloma. Multiple myeloma is a heterogeneous disease with highly variable clinical outcomes. Detecting cytogenetic abnormalities like the t(4;14) translocation allows oncologists to classify the disease into high-risk or standard-risk categories. Patients presenting with symptoms such as bone pain, unexplained fractures, anemia, renal impairment, or hypercalcemia undergo this test to determine the underlying genetic driver of their plasma cell proliferation, aiding in precise prognostic formulation.

Evaluation of Monoclonal Gammopathy of Undetermined Significance

Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) are asymptomatic precursor states that can progress to active multiple myeloma. Clinicians utilize FISH testing, including the t(4;14) probe, to evaluate the risk of malignant transformation. The presence of t(4;14) in precursor states indicates a significantly higher probability of rapid progression to symptomatic myeloma, prompting closer clinical monitoring and early therapeutic intervention strategies.

Monitoring Minimal Residual Disease and Disease Relapse

During or after chemotherapy, autologous stem cell transplantation, or targeted immunotherapy, physicians perform follow-up bone marrow examinations. Running the t(4;14) FISH test during these intervals helps assess the clearance of the malignant clone. If the translocation remains detectable or re-emerges after a period of remission, it indicates minimal residual disease (MRD) or early disease relapse, allowing oncologists to adjust the treatment regimen before clinical symptoms manifest.

Guiding Targeted and Risk-Adapted Therapeutic Decisions

Modern myeloma therapy relies heavily on risk-adapted protocols. Patients harboring the t(4;14) translocation often show a poor response to conventional chemotherapy but may benefit significantly from proteasome inhibitor-based regimens (such as bortezomib, carfilzomib) combined with immunomodulatory drugs. Identifying this translocation early helps oncologists select the most effective drug combinations, avoiding ineffective treatments and minimizing unnecessary toxicity for the patient.

Investigational and Clinical Research Protocols

Given the ‘Research purpose only’ designation in specific laboratory contexts, this test is frequently performed as part of clinical trials, academic research, and epidemiological studies in Pakistan. Researchers and clinical trial investigators utilize this precise FISH assay to evaluate the efficacy of novel targeted therapies, study clonal evolution, and compile cytogenetic data within the Pakistani patient population, contributing to global oncological research.

What Does a t(4:14) by FISH Detect?

The t(4;14) by FISH (Research purpose only) at Chughtai Lab is designed to detect and analyze a wide spectrum of cytogenetic and molecular parameters, including:

• Presence of the t(4;14)(p16.3;q32) translocation.
• Absence of the t(4;14) chromosomal rearrangement.
• Percentage of interphase nuclei positive for the translocation.
• Fusion of the FGFR3 gene on chromosome 4p16.3 and the IGH gene on chromosome 14q32.
• Dual-color dual-fusion signal patterns indicating typical translocation.
• Atypical or variant signal patterns suggesting complex rearrangements.
• Deletion of the derivative chromosome 14 or derivative chromosome 4.
• Monosomy or deletion of chromosome 14q32 locus.
• Amplification or duplication of the FGFR3 gene locus.
• Amplification or duplication of the IGH gene locus.
• Co-existing cytogenetic abnormalities within the analyzed plasma cells.
• Presence of normal diploid cell populations.
• Percentage of abnormal plasma cells relative to total analyzed nuclei.
• Hybridization efficiency and quality of the fluorescent signals.
• Background noise and non-specific binding levels.
• Cell viability and adequacy of the bone marrow or blood specimen.
• Interphase cytogenetic status of non-dividing plasma cells.
• Clonal heterogeneity within the plasma cell population.
• Presence of subclonal populations harboring the t(4;14) translocation.
• Structural integrity of the 4p16 and 14q32 chromosomal regions.
• Correlation with plasma cell enrichment or sorting efficiency (if CD138+ selection is performed).
• Total number of evaluable nuclei (typically 100-200 cells).
• Technical validation parameters of the specific FISH probes used.
• Absence or presence of cross-hybridization artifacts.
• Specific signal configurations (e.g., 1R1G2F, where R is red, G is green, and F is fusion).

Turnaround Time and Report Access at Chughtai Lab

At Chughtai Lab, we understand the critical nature of molecular cytogenetic testing for oncology patients. The t(4;14) by FISH (Research purpose only) is a highly complex molecular assay that requires meticulous processing, hybridization, and expert interpretation by qualified pathologists. Consequently, the turnaround time for this specialized test is typically within 7 to 10 working days. Chughtai Lab offers seamless and convenient ways for patients and clinicians to access reports. Once the analysis is finalized, patients receive an automated SMS notification. Reports can be securely downloaded from the official Chughtai Lab website (chughtailab.com) or through the Chughtai Active Mobile App. Additionally, physical copies of the reports can be collected from any of our conveniently located diagnostic centers across Lahore, Karachi, Islamabad, and other major cities in Pakistan.

t(4:14) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
FGFR3/IGH Fusion	Negative (No fusion signals detected)	Positive (Presence of fusion signals indicating t(4;14))
Positive Nuclei Percentage	0% (Below established laboratory cutoff)	Elevated percentage (e.g., >10% of analyzed cells)
Signal Pattern	Two separate green and two separate red signals (2G2R)	Dual fusion signals (e.g., 1G1R2F or atypical patterns)
FGFR3 Gene Status	Normal copy number (two signals per cell)	Amplification, deletion, or rearrangement of 4p16.3
IGH Gene Status	Normal copy number (two signals per cell)	Rearrangement, deletion, or duplication of 14q32
Specimen Adequacy	Adequate number of viable plasma cells (>100 nuclei)	Inadequate cellularity or poor hybridization quality
Clonal Status	Homogeneous normal cell population	Clonal heterogeneity with subclonal t(4;14) populations
Co-existing Aberrations	None detected	Detection of other high-risk markers (e.g., del(17p))

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for t(4:14) by FISH?

• Experienced healthcare professionals and consultant pathologists specializing in molecular cytogenetics.
• Patient-focused care ensuring comfort and clarity throughout the diagnostic journey.
• Quality diagnostic services utilizing advanced molecular pathology platforms.
• Professional reporting with detailed interpretations of complex cytogenetic findings.
• Modern diagnostic approach integrating state-of-the-art FISH technology.
• Comfortable environment at all collection centers across Pakistan.
• Convenient location with an extensive network of labs and collection points nationwide.
• Commitment to accurate diagnosis, supporting clinicians in critical therapeutic decisions.